in CHF millions
>
in CHF millions
in CHF millions
in CHF millions
in CHF millions
in CHF millions
in CHF millions
>
in CHF millions
>
in CHF millions
in CHF millions
in EUR millions
in CHF millions
>
in CHF millions
in CHF millions
in CHF millions
New developments in medicine are coming thick and fast. Technological advances are increasingly making it possible to understand diseases and the processes taking place in the human body down to the level of individual genes and cells. This brings definite benefits for patients. The earlier an accurate diagnosis can be made and the more precisely a disease can be treated, the greater the prospects of a cure or an improvement in the patient’s quality of life. Nowadays, treatments can be tailored to individual patients more and more effectively. This is what is known as precision medicine and the pioneering field in this area is oncology. We now know that every tumor is unique. If we can analyze the genome of tumor cells, for example, we will have a better chance of making a targeted attack on their weak points.
Those looking to found a spin-off based on a medical innovation will find excellent conditions in Zurich. Researchers benefit from the outstanding infrastructure at the universities and the advantages of the region as a business hub. University Medicine Zurich is a driving force in this dynamic innovation landscape. Through the Translational Medicine Accelerator (TMA), it offers tailored support to accelerate the development of marketable applications or products from research results. Additionally, the TMA provides a valuable network that connects industry and investors. This commitment contributes sustainably to strengthening the region by creating highly qualified jobs and improving healthcare – even on a global scale.
Numerous spin-offs in Zurich demonstrate how the step into entrepreneurship can succeed. With targeted support, they have brought their medical innovations to market. Our series showcases some of these successes.
Those looking to found a spin-off based on a medical innovation will find excellent conditions in Zurich. Researchers benefit from the outstanding infrastructure at the universities and the advantages of the region as a business hub. University Medicine Zurich is a driving force in this dynamic innovation landscape. Through the Translational Medicine Accelerator (TMA), it offers tailored support to accelerate the development of marketable applications or products from research results. Additionally, the TMA provides a valuable network that connects industry and investors. This commitment contributes sustainably to strengthening the region by creating highly qualified jobs and improving healthcare – even on a global scale.
Numerous spin-offs in Zurich demonstrate how the step into entrepreneurship can succeed. With targeted support, they have brought their medical innovations to market. Our series showcases some of these successes.
To help close the gap between scientific research and use in practice, UMZH is offering interested spin-offs an opportunity to improve their competitiveness with the Translational Medicine Accelerator (TMA).
With their «OctoPatch» suction cup, Nevena Paunović and David Klein Cerrejon want to revolutionize how people take their medication. Their spin-off, known as «OBaris», is about to enter its first clinical study.
Each year, some 6,000 to 7,000 babies are born prematurely in Switzerland. This equates to around eight percent of all deliveries. These early arrivals often suffer from a lack of oxygen. The start-up known as OxyPrem has developed a device that accurately measures oxygen levels and can therefore help save lives.
It is well known that men are not keen on visiting the doctor, and urologists in particular. So there is a risk of prostate cancer being detected too late. A simple urine test may be able to minimize the risk in future. This test is being developed by the ONTRACK Biomedical spin-off.
Together with three partners, Jana Fischer has taken the bold step of founding a company and entering the world of private enterprise. The tumor diagnostics services offered by her company «Navignostics» will be available in Switzerland from 2025 and will help treatment providers make better-informed decisions.